Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts

Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma

(2012) E. Tiacci et al.   BLOOD

Phase II study of sorafenib in patients with relapsed or refractory lymphoma

(2012) Anna Guidetti et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cancer treatment and survivorship statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

New therapeutic targets and treatment strategies

(2012) Paula Cramer et al.   Nature Reviews Clinical Oncology

Perifosine as a Potential Novel Anti-Cancer Agent Inhibits EGFR/MET-AKT Axis in Malignant Pleural Mesothelioma

(2012) Giulia Pinton et al.   PLoS One

AIF-mediated caspase-independent necroptosis requires ATM and DNA-PK-induced histone H2AX Ser139 phosphorylation

(2012) M Baritaud et al.   Cell Death & Disease

Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression

(2011) Young-Sun Kim et al.   BIOCHEMICAL PHARMACOLOGY

Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells

(2011) M. D. Bareford et al.   CANCER RESEARCH

Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy

(2011) D Vara et al.   CELL DEATH AND DIFFERENTIATION

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial

(2011) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Oncogenic Stress Induced by Acute Hyper-Activation of Bcr-Abl Leads to Cell Death upon Induction of Excessive Aerobic Glycolysis

(2011) Michael A. Dengler et al.   PLoS One

Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature

(2010) C. Lavazza et al.   BLOOD

Necroptosis as an alternative form of programmed cell death

(2010) Dana E Christofferson et al.   CURRENT OPINION IN CELL BIOLOGY

Emerging drugs for Hodgkin's lymphoma

(2010) Boris Böll et al.   EXPERT OPINION ON EMERGING DRUGS

Developments in the management of Hodgkin's lymphoma

(2010) Lisa Lowry et al.   LANCET

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis

(2010) Tri K. Nguyen et al.   LEUKEMIA RESEARCH

Beyond chemotherapy: new agents for targeted treatment of lymphoma

(2010) Anas Younes   Nature Reviews Clinical Oncology

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

(2009) David T. Teachey et al.   BRITISH JOURNAL OF HAEMATOLOGY

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

(2009) Michael Dickinson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

(2009) Alison J. Moskowitz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy

(2009) L. Fu et al.   CANCER RESEARCH

Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation

(2009) YoungSik Cho et al.   CELL

In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

(2009) K. P. Hoeflich et al.   CLINICAL CANCER RESEARCH

Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms

(2009) T. Walker et al.   MOLECULAR PHARMACOLOGY

Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib

(2009) Constantine S. Mitsiades et al.   SEMINARS IN HEMATOLOGY

Perifosine: Update on a novel Akt inhibitor

(2009) Joell J. Gills et al.   Current Oncology Reports

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

(2009) A. Younes   Hematology-American Society of Hematology Education Program

Perifosine induces differentiation and cell death in prostate cancer cells

(2008) Daniel Floryk et al.   CANCER LETTERS

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

(2008) F Chiarini et al.   LEUKEMIA

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

(2008) Scott M. Wilhelm et al.   MOLECULAR CANCER THERAPEUTICS

Identification of RIP1 kinase as a specific cellular target of necrostatins

(2008) Alexei Degterev et al.   Nature Chemical Biology

Management of Hodgkin Lymphoma in Relapse after Autologous Stem Cell Transplant

(2008) M. Crump   Hematology-American Society of Hematology Education Program